learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Search
forLearn
5 / 14 resultslearn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn sh-Polypeptide-7
learn Rapamycin
mTOR regulator and immunosuppressant used more recently for anti-aging and hair regrowth
learn Overview
Research
5 / 1000+ results
research Can Dermal Delivery of Therapeutics Be Improved Using Thermoresponsive Nanogels?
Thermoresponsive nanogels show promise for delivering medicine through the skin but need more safety testing and regulatory approval before clinical use.
research Where It All Went Right: Secondary Uses of Drugs
Some drugs have gained approval for new uses, while others like tricyclic antidepressants and aspirin show promise but aren't yet approved for these uses.
research Use of Exosomes in Hair Therapy: A Systematic Review
Exosomes may improve hair growth, but more research is needed for safety and approval.
research International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women
Testosterone can help premenopausal and postmenopausal women with low sexual desire, but its long-term safety is unclear and it's not widely approved for this use.
research Advancing Aesthetic Medicine Through Exosome-Based Regenerative Therapies With Dr. Face Innovations: Molecular Mechanisms, Nanotechnology Integration, And Data-Driven Insights
Exosome therapies improve skin, hair, and healing but face challenges like cost and regulation.
Community Join
5 / 123 resultscommunity Coegin Pharma to release Follicopeptide (FOL005) by Q2 2025
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.
community Update July 2025] Most Promising Hair Loss Treatments in Clinical Trials
Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.
community Epibiotech will now offer off-the-shelf allogeneic hair multiplication treatment in South Korea
Epibiotech will offer off-the-shelf allogeneic hair multiplication treatment in South Korea, using dermal papilla cells from donors to grow hair in balding areas. This method is cheaper and less invasive than traditional hair transplants.
community Petition: Make PP405 available tomorrow instead of 2030
PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.
community I hope ET-02 or PP405 will be released in the next 4-5 years
PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.